March 2024
1. HANTEL A, Brunner AM, Plascak JJ, Uno H, et al
   Race/ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia.
   J Natl Cancer Inst. 2024 Mar 22:djae067. doi: 10.1093.
   

   >> Share

   
   January 2024
2. MAILLARD M, Nishii R, Yang W, Hoshitsuki K, et al
   Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations.
   J Natl Cancer Inst. 2024 Jan 16:djae004. doi: 10.1093.
   

   >> Share

   
   December 2023
3. JONES RR, Madrigal JM, Troisi R, Surcel HM, et al
   Maternal serum concentrations of per- and polyfluoroalkyl substances and childhood acute lymphoblastic leukemia.
   J Natl Cancer Inst. 2023 Dec 13:djad261. doi: 10.1093.
   

   >> Share

   
   November 2023
4. SIEGEL DA, King JB, Lupo PJ, Durbin EB, et al
   Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019.
   J Natl Cancer Inst. 2023;115:1337-1354.
   

   >> Share

   
   June 2023
5. UMARETIYA PJ, Koch VB, Flamand Y, Aziz-Bose R, et al
   Disparities in parental distress in a multicenter clinical trial for pediatric acute lymphoblastic leukemia.
   J Natl Cancer Inst. 2023 Jun 1:djad099. doi: 10.1093.
   

   >> Share

   
   June 2022
6. KEATING NL, Brooks GA, Landrum MB, Liu PH, et al
   The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.
   J Natl Cancer Inst. 2022;114:871-877.
   

   >> Share

   
   May 2022
7. ZHAO X, Qian M, Goodings C, Zhang Y, et al
   Molecular mechanisms of ARID5B-mediated genetic susceptibility to acute lymphoblastic leukemia.
   J Natl Cancer Inst. 2022 May 16. pii: 6586299. doi: 10.1093.
   

   >> Share

   
   
8. RODWIN RL, Kairalla JA, Hibbitts E, Devidas M, et al
   Persistence of chemotherapy-induced peripheral neuropathy despite vincristine reduction in childhood b-acute lymphoblastic leukemia.
   J Natl Cancer Inst. 2022 May 12. pii: 6584828. doi: 10.1093.
   

   >> Share

   
   March 2022
9. GARCIA-PRIETO CA, Villanueva L, Bueno-Costa A, Davalos V, et al
   Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies.
   J Natl Cancer Inst. 2022;114:436-445.
   

   >> Share

   
   October 2021
10. LIPSYC-SHARF M, Zhang S, Ou FS, Ma C, et al
    Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    J Natl Cancer Inst. 2021 Oct 12. pii: 6390822. doi: 10.1093.
    

    >> Share

    
    September 2021
11. EFFICACE F, Baccarani M
    Quality of Life Improvements in Patients with Chronic Myeloid Leukemia after Stopping Long-Term Therapy: Who Can Benefit the Most?
    J Natl Cancer Inst. 2021 Sep 7. pii: 6365945. doi: 10.1093.
    

    >> Share

    
    
12. SCHOENBECK KL, Atallah E, Lin L, Weinfurt KP, et al
    Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors.
    J Natl Cancer Inst. 2021 Sep 7. pii: 6365943. doi: 10.1093.
    

    >> Share

    
    May 2021
13. VAN DER PLAS E, Qiu W, Nieman BJ, Yasui Y, et al
    Sex-Specific Associations Between Chemotherapy, Chronic Conditions, and Neurocognitive Impairment in Acute Lymphoblastic Leukemia Survivors: A Report From the Childhood Cancer Survivor Study.
    J Natl Cancer Inst. 2021;113:588-596.
    

    >> Share

    
    October 2020
14. DUSETZINA SB, Huskamp HA, Jazowski SA, Winn AN, et al
    Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers.
    J Natl Cancer Inst. 2020;112:1055-1062.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share